Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Enanta Pharmaceutica
(NQ:
ENTA
)
12.13
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Enanta Pharmaceutica
< Previous
1
2
3
4
Next >
10 Companies That Had Tons of Money in SVB When It Collapsed
March 13, 2023
Silicon Valley Bank is gone but its clients are still here. Many prominent companies, and not just startups, had money in SVB.
Via
InvestorPlace
Enanta Pharmaceuticals's Earnings: A Preview
February 06, 2023
Via
Benzinga
Earnings Scheduled For November 21, 2022
November 21, 2022
Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million.
Via
Benzinga
Earnings Outlook For Enanta Pharmaceuticals
November 18, 2022
Via
Benzinga
Recap: Enanta Pharmaceuticals Q3 Earnings
August 08, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Analyst Ratings for Enanta Pharmaceuticals
July 01, 2022
Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings for Enanta Pharmaceuticals
June 01, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Where Enanta Pharmaceuticals Stands With Analysts
February 09, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:
Via
Benzinga
What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals
August 01, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
July 29, 2022
Via
Benzinga
Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study
July 29, 2022
Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple...
Via
Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
July 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants
July 29, 2022
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a...
Via
Benzinga
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
July 07, 2022
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022
July 06, 2022
Upgrades
Via
Benzinga
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
June 28, 2022
Via
Benzinga
Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid
June 22, 2022
Another company says it invented the technology behind the pill first.
Via
Investor's Business Daily
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
June 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
June 01, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
May 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint
May 18, 2022
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
May 10, 2022
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.
Via
Benzinga
Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial
February 16, 2022
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a...
Via
Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
February 11, 2022
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.
Via
Investor's Business Daily
Enanta Pharmaceuticals: Q1 Earnings Insights
February 08, 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals
January 13, 2022
Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Thursday
January 13, 2022
RBC Capital boosted KB Home (NYSE: KBH) price target from $46 to $55. KB Home shares rose 6.7% to $45.20 in pre-market trading. Cowen & Co. reduced the price target on...
Via
Benzinga
7 A-Rated Biotechs to Buy for the Long Run
December 03, 2021
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.
Via
InvestorPlace
Where Enanta Pharmaceuticals Stands With Analysts
November 24, 2021
Over the past 3 months, 11 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ:
Via
Benzinga
Earnings Scheduled For February 8, 2022
February 08, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.